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Abstract
The RIP kinases have emerged as essential mediators of cellular stress that integrate both extracellular stimuli emanat-
ing from various cell-surface receptors and signals coming from intracellular pattern recognition receptors. The molecular
mechanisms regulating the ability of the RIP proteins to transduce the stress signals remain poorly understood, but seem
to rely only partially on their kinase activities. Recent studies on RIP1 and RIP2 have highlighted the importance of
ubiquitination as a key process regulating their capacity to activate downstream signaling pathways. In this study, we found
that XIAP, cIAP1 and cIAP2 not only directly bind to RIP1 and RIP2 but also to RIP3 and RIP4. We show that cIAP1 and cIAP2
are direct E3 ubiquitin ligases for all four RIP proteins and that cIAP1 is capable of conjugating the RIPs with diverse types of
ubiquitin chains, including linear chains. Consistently, we show that repressing cIAP1/2 levels affects the activation of NF-kB
that is dependent on RIP1, -2, -3 and -4. Finally, we identified Lys51 and Lys145 of RIP4 as two critical residues for cIAP1-
mediated ubiquitination and NF-kB activation.
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Introduction
Cells are continuously confronted with stress signals that initiate
at the cell surface or within the cell. The ability to transduce the
signal and to activate a cellular response, either through trans-
cription-dependent or –independent mechanisms, relies on the
recruitment of adaptor proteins to the extra- and intra-cellular
sensors. Among these adaptors, members of the receptor-inter-
acting protein kinase (RIP) family have emerged as essential
mediators of cellular stress. All RIP kinases contain a kinase
domain that is conserved between the family members and bear
unique domains that allow protein-protein interactions[1]. RIP1,
the first identified member of the RIP kinase family, was shown to
participate in the signaling pathways activated downstream of
several members of the TNF receptor superfamily[2], Toll-like
receptors (TLR) 3 and 4[2,3], and after genotoxic stress[4]. RIP1
can mediate gene transcription through activation of the MAPK
and NF-kB signaling pathways, and can induce cell death by the
formation of death complexes. Similarly, RIP2 (CARDIAK/
RICK) was shown to participate in the activation of the MAPK
and NF-kB signaling pathways downstream of the innate immune
pattern recognition receptors NOD1 and NOD2[5,6,7], and to be
part of a pro-apoptotic complex activated by NOD1[8]. RIP2 is
also required for optimal T-Cell Receptor (TCR) signaling and,
although controversial, was reported to mediate TLR respons-
es[5,6,7,9]. Mice lacking RIP3 do not develop spontaneous
phenotypic manifestations[10], but this kinase has been reported
to be a major player in the execution of a caspase-independent
type of cell death called necroptosis[11,12,13]. In addition, the
ectopic expression of RIP3 in cells was shown to induce apoptosis
and NF-kB activation[14,15]. RIP4 (PKK/DIK) also induces
JNK and NF-kB when ectopically expressed[16,17], but the
pathways that lead to activation of RIP4 remain unidentified.
Transgenic studies have indicated that this kinase plays a role in
proper skin development and inflammatory responses[18,19].
The ability of RIP1 and RIP2 to transduce stress signals was
shown to rely only partially on their catalytic activities. Just like
RIP1, the kinase activity of RIP2 is not required for the NF-kB
response or for the activation of JNK and p38 [9,20,21]. Recent
studies have highlighted the importance of ubiquitination as a key
process regulating RIP1 and RIP29s capacity to activate
downstream signaling pathways[22,23,24]. Ubiquitination is a
post-translational modification involving covalent attachment of
ubiquitin, a 76-amino acid polypeptide, to a target protein by a
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e22356
cascade of reactions carried out by the concerted action of
the ubiquitin-activating (E1), -conjugating (E2) and -ligating
(E3) enzymes[25]. Protein ubiquitination is emerging as a key
regulatory mechanism that controls many physiological processes,
including protein degradation, cell signaling, DNA damage
response, and protein trafficking. This wide range of consequences
originates from the ability of ubiquitin to form polymers in which
an internal Lys residue of one ubiquitin moiety is attached to the
carboxy-terminal residue of another. Primarily, Lys48-linked and
Lys63-linked polyubiquitin modifications have been studied, and
these linkages are respectively known to be required for
proteasomal degradation and signal transmission. Recently,
attention has been paid to a new type of ubiquitin chain that
plays a role in NF-kB activation – the linear ubiquitin chains,
arising from attachment of the C-terminal Gly to the N-terminal
Met. So far, LUBAC is the only E3 ubiquitin ligase complex
reported to conjugate substrates with linear ubiquitin
chains[26,27].
Inhibitor of apoptosis proteins (IAPs) are phylogenetically
conserved proteins characterized by the presence of at least one
Baculovirus IAP Repeat (BIR) motif, a zinc-binding structure of
approximately 70 amino acid residues that mediates protein-
protein interactions[28]. As indicated by their name, the function
of these proteins was first believed to be restricted to inhibition of
cell death, mostly by direct interference with the proteolytic
activities of caspases. However, several studies later proved that
IAPs have a much wider spectrum of action, and that XIAP is
probably the only member capable of direct caspase inhibition. In
addition to their BIR domains, an interesting feature of XIAP,
cIAP1 and cIAP2 is the presence of a RING finger domain
conferring E3 ubiquitin ligase activity. Cellular IAP proteins can
promote Lys48- and Lys63-linked polyubiquitination of RIP1 and
RIP2[29,30,31,32]. The addition of Lys63-linked ubiquitin chains
to these proteins was reported to create a platform for the
recruitment and activation of the TAB-TAK1 complex and of the
IkB Kinase (IKK) complex IKKa-IKKb-NEMO, which drives
NF-kB activation and thereby induces gene transcription [22,23].
However, recent studies have shown that Lys63-linked ubiquitin
chains might not be essential for NF-kB activation, suggesting
existence of other chain types for the recruitment and activation of
the these kinase complexes[35,36]. Interestingly, cIAP1 has been
shown to induce Lys6-, Lys11-, Lys48-, and Lys63-auto-ubiqui-
tination, and a recent study demonstrated the ability of cIAP1 to
conjugate RIP1 with Lys11-linked ubiquitin chains[33,37]. In
addition, cIAP1/2-mediated ubiquitination of RIP1 was also
reported to prevent RIP1 from integrating and activating death
complexes[31,38].
The molecular mechanisms regulating RIP3 and RIP4
functions remain poorly understood, and whether ubiquitination
plays a regulatory function is unknown. Because IAPs were shown
to be critical regulators of RIP1 and RIP2, we investigated
whether they also participate in the regulation of RIP3- and RIP4-
mediated functions. We found that XIAP, cIAP1 and cIAP2 bind
to RIP3 and RIP4, and that cIAP1 and cIAP2 function as direct
E3-ubiquitin ligases for all four RIP proteins. By performing in vitro
ubiquitination reactions, we found that cIAP1 not only conjugate
RIP proteins with Lys48- and Lys63-linked polyubiquitin chains
but also with head-to-tail linear ubiquitin chains. Consistent with
these findings, we found that repressing cIAP1/2 levels by the use
of the IAP antagonist BV6 attenuated activation of NF-kB that is
dependent on RIP1, -2, -3 and -4 (hereafter RIP1–4). Finally, we
identified two lysines of RIP4 that play a critical role in cIAP1-
mediated ubiquitination and NF-kB activation. Together, our
results provide new insights into the regulatory mechanisms
controlling the members of the RIP family.
Materials and Methods
Plasmids
We are grateful to Prof. J. Tschopp for providing us with the
VSV-tagged human RIP1-RIP4 plasmids. The plasmids encoding
RIP4 mutants were generated from a pCR3 construct encoding
VSV-tagged wild-type human RIP4 by using the QuickChange
mutation kit (Stratagene). The primer pairs used to generate the
K-R amino acid changes are as follow:
K145R: 59-ctgcacctggacctcaggccggcgaacatcctgctg-39 and 59-
cagcaggatgttcgccggcctgaggtccaggtgcag-39, K158R: 59-gcccactac-
cacgtcaggatttctgattttggt-39 and 59-accaaaatcagaaatcctgacgtgg-
tagtgggc- 39, K220-221R: 59-ggcgtgctcacacagaggaggccgtttgcagat-
gag-39 and 59-ctcatctgcaaacggcctcctctgtgtgagcacgcc-39
Pull-down, immunoprecipitation and immunoblotting
experiments
Pull-downs: VSV-tagged RIP proteins were produced in vitro
with a TnT T7 quick-coupled transcription and translation system
(Promega, Cat# L-4610) in the presence of 35S-methionine
(Perkin Elmer, Cat# NEG-709A). GST, GST-XIAP, GST-
cIAP1, and GST-cIAP2 fusion proteins were produced in bacteria
from pGEX4T2 constructs and purified using glutathione
sepharose 4FF beads (Amersham GE Healthcare, Cat# 17-
5132-01). Pull-down assays were performed in NP40 buffer
(10 mM Tris pH 8.0, 150 mM NaCl, and 1% Nonidet P-40)
supplemented with protease and phosphatase inhibitor tablets
(Roche, Cat # 11873580001, # 04906837001).
Immunoprecipitation: HEK293T cells[39] were transfected
with the appropriate plasmids using a standard calcium phosphate
protocol and lysed in NP40 buffer 24 h post-transfection.
Coimmunoprecipitations were performed in presence of either
anti-FLAG M2 Affinity Gel (beads) (Sigma, Cat# A2220) or
protein G sepharose 4FF beads (GE Healthcare, Cat # 17-0618-
01) coupled to Myc 9E10 monoclonal antibody (produced in our
lab). SDS-polyacrylamide gel electrophoresis and immunoblotting
were performed in accordance with standard protocols. For
immunoblotting, we used anti-VSV and anti-FLAG antibodies
from Sigma (Cat# V 4888, F7425). The anti-cIAP1 antibody was
obtained from Dr. J Silke (La Trobe University), and the anti-
ubiquitin-HRP antibody was purchased from ENZO Life Sciences
– Biomol (Cat# PW0150). Direct immunoprecipitations were
performed in RIPA buffer (10 mM Tris [pH 8.0], 150 mM NaCl,
1% Nonidet P-40, 0.1% SDS, and 0.5% deoxycholate).
Lambda-phosphatase treatment: A plasmid encoding Flag-
tagged RIP4 was transfected into HEK293T cells[39]. 24h later
lysates were made and RIP4 was affinity purified, making use of
Flag-M2-beads (Sigma). Afterwards the beads were washed with
PBS and incubated in presence or absence of 100U of l-
phosphatase (Biolabs) for 1 hour according to the manufacturer’s
protocol. Samples were loaded on SDS-PAGE and submitted to
western blotting with anti-Flag antibody for detection.
In vitro ubiquitination assays
VSV-tagged RIP proteins were produced in vitro with a TnT T7
quick coupled transcription and translation system (Promega,
Cat# L-4610) in the presence of 35S- methionine (Perkin Elmer,
Cat# NEG-709A). GST, GST-XIAP, GST-cIAP1, and GST-
cIAP2 fusion proteins were produced in bacteria from pGEX4T2.
In vitro ubiquitination reactions were carried out at 37uC for
60 min in 75 mM Tris pH 8, 2 mM DTT, 5 mM MgCl2, 4 mM
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ATP, 50 nM E1 (Boston Biochem Cat# E-305), 0.2 mM ubiquitin
(WT, K48-only, K63-only, K0, Myc-tagged) (Boston Biochem
Cat# U-100H, UM-K480, UM-K630, UM-NOK, U-115),
0.5 mM UbcH5a E2 (Boston Biochem Cat. # E2-616),
0.03 mg/ml E3 and 20% of the Myc-tagged RIP TnT reaction
product. After incubation at 37uC for 1h, the reaction products are
boiled in presence of Laemmli buffer and run on 8% acrylamide
gels. The gels are then fixed (10% acetic acid, 40% Methanol in
water), dried and exposed. RIP ubiquitination was revealed by
autoradiography and appears as a smear in the figure.
NF-kB luciferase assays
HEK293T cells[39] were transfected with the indicated
expression vectors combined with 100 ng of reporter plasmids
for NF-kB-luciferase and pACT-b-galactosidase. Where indicated,
1 mM BV6 was added 8 h after transfection. The cells were
stimulated with TNF for 4 h using 10,000 U/ml of hTNF.
Twenty-four hours post transfection, the cells were collected,
washed in PBS and lysed in Luciferase lysis buffer (25 mM Tris
phosphate pH 7.8, 2 mM DTT, 2 mM CDTA, 10% glycerol and
1% Triton-X-100). Substrate buffer was added (658 mM luciferin,
378 mM coenzyme A and 742 mM ATP) and Luciferase activity
(Luc) was assayed in a GloMax 96 Microplate Luminometer
(Promega). b-Galactosidase (Gal) activity in cell extracts was
assayed with chlorophenol red b-D-galactopyranoside substrate
(Roche Applied Science, Basel, Switzerland) and the optical
density was read at 595 nm in a Benchmark microplate Reader
(Bio-Rad Laboratories, Nazareth, Belgium). Luc values were
normalized for Gal values to correct for differences in transfection
efficiency (plotted as Luc/Gal). The untreated or wild type
condition was set as 100. The data represent the average6 S.D. of
triplicates.
Results
XIAP, cIAP1 and cIAP2 physically interact with RIP3 and
RIP4
Previous studies have shown that XIAP, cIAP1 and cIAP2 bind
to RIP2 by association through the kinase domain[29,40], which
suggests that other members of the RIP family can also bind to
these IAPs. To test whether RIP3 and RIP4 directly bind
these IAPs, we performed pull-down experiments using bac-
terially produced GST-XIAP, GST-cIAP1 and GST-cIAP2 fusion
proteins and in vitro-transcribed and -translated radiolabeled RIP3
and RIP4. Purified GST was used to assess nonspecific binding
and RIP1 and RIP2 were used as positive controls. As previously
reported, RIP1 interacted with GST-XIAP and displayed even
higher affinity for GST-cIAP1 and GST-cIAP2 (Figure 1A). RIP2
bound to GST-cIAP1 and to a lesser extent to GST-XIAP and
GST-cIAP2. Interestingly, we found that RIP3 and RIP4 could
also directly interact with these three GST-IAPs. Association of
cIAP2 and RIP2 was reported to require a two-site interaction
involving regions in both the BIR domains and the CARD-RING
domain of cIAP2[29]. The SMAC binding site of the BIR2
domain of XIAP was shown to be crucial for RIP2 binding, and
the association of XIAP with RIP2 could be inhibited in presence
of a SMAC mimetic compound [40]. In order to test whether the
use of the SMAC mimetic BV6 could also inhibit binding of the
IAPs to the other RIPs, we included BV6 in another set of pull-
down experiments[41]. As shown in figure 1B, the presence of
BV6 greatly reduced the binding of XIAP to RIP2 but had not
impact on the association of XIAP with RIP1, RIP3 or RIP4. The
presence of BV6 also greatly inhibited binding of cIAP1 and
cIAP2 to RIP1 and RIP2, but had no influence on their
association with RIP3 and RIP4. Together, these results indicate
that the IAPs use different binding motifs for their association with
the different RIPs. In addition, these experiments also provide
information on the relative affinity of each IAP for the different
RIPs: cIAP1: R1=R2.R4.R3; cIAP2: R1.R2=R4.R3;
XIAP: R4=R2.R3.R1.
To address whether cIAP1 and cIAP2 interact with RIP3 and
RIP4 also in cells, we performed immunoprecipitation experi-
ments with lysates of HEK293T cells overexpressing the different
RIPs in the absence or presence of cIAP1 or cIAP2. As shown in
Figures 1C and 1D, all four RIPs co-immunoprecipitated with
cIAP1 or cIAP2. The pre-mentioned relative affinity of cIAP2 for
RIP1-4 was also confirmed in a cellular context (Figure S1).
cIAP1 and cIAP2 are direct E3 ubiquitin ligases for RIP1–4
We recently described a crucial role for cIAP1/2 in RIP1- and
RIP2-signaling pathways, and showed that cIAP1/2 can act as
direct E3 ubiquitin ligases for RIP1[29,31]. In the current study,
we tested whether XIAP, cIAP1 or cIAP2 could also act as direct
E3 ligases for RIP2–4 by performing in vitro ubiquitination assays.
To do so, we incubated 35S-methionine-labeled RIPs, transcribed
and translated in vitro, with bacterially produced GST-XIAP,
GST-cIAP1 and GST-cIAP2, and used UbcH5a as E2 compo-
nent. As shown in Figure 2A, no ubiquitination was observed in
absence of E3 enzyme (beads alone (-) or GST alone) and, as
previously described, RIP1 was a direct substrate for cIAP1 and
cIAP2[30,31,32]. Interestingly, we found that addition of GST-
cIAP1 also strongly induced ubiquitination of the other three
RIPs. The presence of GST-cIAP2 resulted in ubiquitination of
RIP2–4, although not as efficiently as GST-cIAP1. On the
contrary, incubation with GST-XIAP only led to weak ubiquitina-
tion of RIP4.
When ectopically expressed in HEK293T cells, cIAP1/2 induce
strong ubiquitination of cIAP2-bound RIP1 and RIP2, detectable
by immunoblot using anti-VSV antibody (Figure S1 and data not
shown). The use of anti-VSV antibody does not allow detection of
ubiquitinated forms of cIAP1/2-bound RIP3 or RIP4, probably
due to the lower affinity of cIAP1/2 for these proteins and
therefore reaching the antibody detection limits. However,
immunoblot using anti-ubiquitin antibody revealed ubiquitin
smears with sizes corresponding to RIP3 and RIP4 (Figure 2B).
We confirmed cIAP2-mediated RIP3 ubiquitination in cells by
Figure 1. XIAP, cIAP1 and cIAP2 bind RIP1-4 proteins. (A) In vitro-transcribed and -translated RIP1, 2, 3 and 4 labeled with 35S-methionine
(Input) was incubated overnight with bacterially produced GST, GST-XIAP, GST-cIAP1, or GST-cIAP2 bound to Sepharose beads. The beads were
washed extensively and run on an acrylamide gel. Binding of RIPs was revealed by autoradiography (pull-down). (B) In vitro-transcribed and -
translated RIP1, 2, 3 and 4 labeled with 35S-methionine (Input) was incubated overnight with bacterially produced GST-XIAP, GST-cIAP1, or GST-cIAP2
bound to Sepharose beads in presence of BV6 (5 mM) or DMSO as a control. The beads were washed extensively and run on an acrylamide gel.
Binding of RIPs was revealed by autoradiography. (C) HEK293T cells were transfected with VSV-tagged RIP plasmids in the absence or presence of a
FLAG-tagged cIAP1 plasmid. cIAP1 was immunoprecipitated in NP-40 buffer using anti-FLAG antibody and coimmunoprecipitated RIPs were revealed
by immunoblotting with anti-VSV antibody. Protein expression in the lysates is shown. (D) HEK293T cells were transfected with VSV-tagged RIP
plasmids in the absence or presence of a Myc-tagged cIAP2 plasmid. cIAP2 was immunoprecipitated in NP-40 buffer using anti-Myc antibody and
coimmunoprecipitated RIPs were revealed by immunoblotting with anti-VSV antibody. Protein expression in the lysates is shown.
doi:10.1371/journal.pone.0022356.g001
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direct immunoprecipitation of RIP3 in RIPA buffer (Figure 2C).
Together these results demonstrate the role of cIAP1/2 as direct
E3 ubiquitin ligases for RIP1–4 in vitro and in a cellular context.
cIAP1 conjugates RIP1–4 with diverse ubiquitin chains,
including head-to-tail linear chains
To identify the type of ubiquitin chains conjugated by cIAP1/2
to the RIPs, we next performed series of in vitro ubiquitination
reactions using ubiquitin variants in which all Lys residues, except
Lys48 or Lys63, were mutated (Figure 3A–B). Because cIAP1
ubiquitinates RIP1–4 more efficiently than cIAP2 in vitro, we
decided to concentrate our work on cIAP1. We found that cIAP1
could induce RIP-ubiquitination irrespectively of the type of
ubiquitin variant used (Figure 3B). This implies that cIAP1
mediates ligation of both Lys48- and Lys63-ubiquitin linkages on
RIP1-4, or, alternatively, that it mediates linear ubiquitination. To
test for the presence of head-to-tail linkages, we performed
ubiquitination assays using a Lys-free ubiquitin variant (KO).
Interestingly, we found that cIAP1-mediated ubiquitination of the
RIPs was not inhibited when using this mutant, which suggests the
presence of linear ubiquitin chains (Figure 3C). Because multi
mono-ubiquitination is another potential explanation for our
observations, we repeated the experiment using Myc-tagged
ubiquitin. This variant does not affect mono-ubiquitination but
inhibits linear chain formation. Figure 3D shows that the use of
Myc-tagged ubiquitin did not inhibit, but repressed cIAP1-
mediated ubiquitination of RIP1 and RIP4. On the other hand,
it only had a minor effect on RIP2 and RIP3 ubiquitination.
Taken together, our data demonstrate that cIAP1 and cIAP2 are
direct E3 ubiquitin ligases for all four RIPs and indicate that
cIAP1 conjugates RIP1–4 with diverse types of ubiquitin chains,
including linear chains.
cIAP1/2 regulate NF-kB activation mediated by RIP1–4
The RIP kinases are involved in several cellular signaling
pathways regulating differentiation, inflammatory responses, and
cell death or survival[42]. A commonality of RIP1–4 is their role
in activating the canonical NF-kB pathway when ectopically
expressed. Lys63-ubiquitination has been reported to be crucial for
this mediatory function of RIP1 and RIP2 because it promotes
assembly of a pro-survival signaling platform that facilitates
TAK1-dependent phosphorylation of the IKKa/IKKb com-
plex[22,23]. cIAP1/2 are positive regulators of TNFR1- and
NOD1/2-induced canonical NF-kB pathway, and are required for
Lys63-ubiquitination of RIP1 and RIP2 [29,30,31,43]. To test
whether RIP3 and RIP4 have to be ubiquitinated by cIAP1/2 in
order to mediate NF-kB activation, we compared RIP-mediated
NF-kB luciferase reporter activity when ectopically expressed in
HEK293T cells in the presence or absence of the IAP inhibitor
BV6, a treatment that induces rapid auto-ubiquitination and
degradation of endogenous cIAP1/2[41]. As shown in Figure 4A,
BV6 treatment greatly impaired TNF and RIP1–RIP4-induced
NF-kB activation but had no impact on TAK1-mediated NF-kB
induction (Figure 4A). Those results, which indicate that cIAP1/2
act upstream of TAK1, are consistent with a role for cIAP1/2 as
E3 ligases regulating RIP1–4-mediated activation of NF-kB.
Ectopic expression of the RIPs has been reported to induce their
auto-phosphorylation and we confirmed phosphorylation of RIP4
by l-phosphatase treatment (Figure 4C). It is important to note
that BV6 treatment did not affect RIP or TAK1 protein
expression levels nor modified the phospho-status of the overex-
pressed RIPs (Figure 4B). Together, our results demonstrate that
depleting cIAP1/2 inhibits RIP1-4 mediated NF-kB activa-
tion without affecting RIP auto-phosphorylation.
Previous studies identified Lys377 in the intermediate domain
(ID) of RIP1 and Lys209 in the kinase domain (KD) of RIP2 as
important residues acting as acceptor sites for Lys63-ubiquitina-
tion and NF-kB activation[22,23]. Other studies identified the C-
terminal region of RIP3 (excluding the KD) and the KD of RIP4
as sufficient for NF-kB activation[15,16,17], indicating that RIP
proteins do not seem to use conserved residues in order to activate
NF-kB. These observations prompted us to look for alternative
ubiquitin acceptor sites on RIP3 and RIP4. Because RIP3 is a
weak inducer of NF-kB, we decided to limit our study to RIP4
and generated a series of full-length RIP4 variants containing a
Lys residue mutation within the KD. We mutated Lys51 (the
ATP-binding pocket), Lys145, Lys158 (upstream of the RIP4 T-
loop) or Lys220/221 to arginines and then tested the ability of
these mutants, when expressed ectopically, to activate NF-kB. As
shown in Figure 5A, expression of K158R and K220/221R
mutants induced NF-kB activation similarly to full-length wild-
type RIP4. On the contrary, mutation of Lys51 (K51R) or Lys145
(K145R) strongly repressed NF-kB activation. Figure 5B shows
that all mutants were expressed at similar levels and that
overexpression of K51R and K145R did not induce phosphory-
lation of RIP4. To correlate these defects of NF-kB activation with
defects of ubiquitination, we ectopically expressed wild-type RIP4
and the K51R mutant in HEK293T cells and compared their
ubiquitination status by immunoblot after immunoprecipitation.
Surprisingly, we found that both RIP4 proteins were highly
ubiquitinated, although with different ubiquitination patterns
(Figure 5C). However, BV6 treatment repressed ubiquitination
of the wild-type RIP4 but not of the K51R mutant. Remarkably, in
vitro ubiquitination assays revealed that cIAP1-mediated ubiquiti-
nation of RIP4 was greatly affected when using K51R or K145R
but not when using K158R or K220/221R (Figure 5D). Together,
our results show that cIAP1/2 regulates RIP1–4-mediated
activation of NF-kB and identify Lys51 and Lys145 of RIP4 as
important residues for cIAP1-mediated ubiquitination and NF-kB
activation.
Discussion
Among the eight IAP members encoded by the human genome,
five contain a carboxy-terminal RING domain that provides them
with E3 ubiquitin ligase activity, and two (cIAP1 and cIAP2) were
shown to regulate RIP1 and RIP2 functions by conjugating them
with ubiquitin chains[28,29,30,31]. XIAP, another RING domain
containing IAP, has also been shown to regulate RIP2-mediated
Figure 2. cIAP1 and cIAP2 are direct E3 ubiquitin ligases for RIP1–4 proteins. (A) In vitro ubiquitination assays were performed on in vitro-
transcribed and -translated RIP1–4 proteins labeled with 35S-methionine. GST, GST-XIAP, GST-cIAP1, or GST-cIAP2 was used as E3 component, UbcH5a
as the E2 component, and using wild-type ubiquitin. RIP ubiquitination was revealed by autoradiography and appears as a smear in the figure. (B)
HEK293T cells were transfected with VSV-tagged RIP3 and RIP4 plasmids in the absence or presence of a Myc-tagged cIAP2 plasmid. cIAP2 was
immunoprecipitated in NP-40 buffer using anti-Myc antibody and coimmunoprecipitated ubiquitinated RIP3 and RIP4 were revealed by
immunoblotting with anti-VSV and anti-ubiquitin antibodies. Protein expression in the lysates is shown. (C) HEK293T cells were transfected with VSV-
tagged RIP3 plasmid in the absence or presence of a cIAP2 plasmid. RIP3 was immunoprecipitated in RIPA buffer using anti-VSV antibody and
ubiquitinated RIP3 was revealed by immunoblotting with anti-VSV and anti-ubiquitin antibodies. Protein expression in the lysates is shown.
doi:10.1371/journal.pone.0022356.g002
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functions, but whether this requires its ligase activity is
unknown[40]. In this study, we report that in addition to RIP1
and RIP2, also RIP3 and RIP4 directly interact with XIAP, cIAP1
and cIAP2. When comparing the ability of these IAPs to directly
conjugate RIP1–RIP4 with ubiquitin chains, we found that cIAP1
was the most effective E3 and was capable of ubiquitinating all
four RIPs in the presence of the E2 component UbcH5a. On the
contrary, XIAP was only capable of inducing weak ubiquitination
of RIP4. However, because other E2 components or additional
adaptor proteins might be required for XIAP to function, we
cannot exclude its potential role as E3 for the RIPs in physiological
settings. The consequence of ubiquitination depends on the type of
ubiquitin chains added to the substrate: Lys48-ubiquitin chains
direct proteins towards proteasomal degradation whereas Lys63-
and linear chains act as docking sites for the activation of signaling
pathways[25]. Using ubiquitin mutants, we were surprised to find
that cIAP1 conjugates the RIPs not only with Lys48- and Lys63-
ubiquitin chains but also with linear chains. The addition of
Lys63-ubiquitin chains to RIP1 and RIP2 was reported to create a
platform for the recruitment of the TAB-TAK1 and IKKa-IKKb-
NEMO complexes[22,23]. The close proximity created on the
ubiquitin chains between TAK1 and IKKb is believed to be
sufficient for TAK1 to activate IKKb by phosphorylation and
therefore activate the NF-kB pathways, implying that TABs and
NEMO ubiquitin binding domains (UBD) are specific for Lys63
chains. However, recent studies indicated that Lys63-ubiquitin
chains might not be essential for TNF-induced NF-kB activation,
and that NEMO possesses high affinity for other ubiquitin chains,
Figure 4. Requirement of cIAP1/2 for RIP1–4-mediated NF-kB activation. (A) NF-kB luciferase assays were performed on lysates from
HEK293T cells transfected with a plasmid encoding the indicated RIP kinase or TAK1. Cells were left untreated or were treated with 1 mM of BV6.
Stimulation with hTNF was used as a positive control. (B) Western blot showing expression of the tagged-RIP kinases, cIAP1 and TAK1 in the lysates.
(C) Phosphorylation of RIP4 was revealed by l-phosphatase treatment of immunopurified Flag-RIP4 overexpressed in HEK293T cells. Samples were
analyzed by western blot using anti-Flag antibody.
doi:10.1371/journal.pone.0022356.g004
Figure 3. cIAP1 conjugates RIP1–4 proteins with Lys48-, Lys63-, and linear ubiquitin chains. (A) Schematic representation of the different
ubiquitin mutants used in the experiments. (B–D) In vitro ubiquitination assays were performed on in vitro-transcribed and -translated RIP1–4 proteins
labeled with 35S-methionine. GST or GST-cIAP1 was used as E3 component and UbcH5a as the E2 component. The reaction was carried out in
presence of (B) wild-type (WT) ubiquitin, K48-only ubiquitin and K63-only ubiquitin; (C) no ubiquitin, wild-type (WT) ubiquitin and lysine free ubiquitin
(KO); (D) no ubiquitin, wild-type (WT) ubiquitin and Myc-tagged ubiquitin. Ubiquitination of the RIPs was revealed by autoradiography.
doi:10.1371/journal.pone.0022356.g003
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including Lys11- and linear chains[33,35,36,44]. Consistent with
this, mass spectrometry analysis revealed that RIP1 is conjugated
with Lys11-, Lys48-, Lys63- and linear ubiquitin chains in the
TNFR signaling complex[33,34]. Interestingly, Dynek et al.
reported cIAP1-mediated Lys11-ubiquitination of RIP1[33], and
we now provide evidence for cIAP1-mediated linear ubiquitina-
tion of RIP1. LUBAC is the only E3 complex identified, so far,
capable of linear ubiquitination[26]. Although LUBAC strongly
ubiquitinates NEMO in vitro, its effect on RIP1 are rather
minor[34], suggesting the existence of other linear-ubiquitinating
enzymes. In our study, we show that cIAP1 strongly ubiquitinates
RIP1 when using the K0 ubiquitin mutant in vitro, suggesting linear
ubiquitin chain conjugation. The reduced ubiquitination observed
when using the Myc-tagged form of ubiquitin supports this idea.
However, mass spectrometry analysis would be required to clearly
identify those chains as being linear. The finding that cIAP1
conjugates RIPs with diverse ubiquitin chains provides new
interpretations of how receptor-signaling complexes might be
assembled. We found that, unlike other RIPs, cIAP1 mediates
mostly Lys63-ubiquitination of RIP2.
Activation of the NF-kB pathway is a property of all RIP family
members, and we used it as a functional read-out to test the role of
cIAP1/2 in the regulation of RIPs functions. Depletion of cIAP1/
2 by BV6 treatment greatly affected RIP1–4-dependent NF-kB
activation, which confirms a role for cIAP1/2 in regulating RIPs
functions. We and others previously reported that cIAP-mediated
ubiquitination of RIP1 prevents RIP1 from integrating and
activating death complexes – either apoptotic or necrotic
[24,30,31,38,43,45]. The physiological relevance of the regulation
of RIP3 functions by cIAP1 and cIAP2 might therefore go beyond
NF-kB activation. Indeed, several recent publications have
highlighted the crucial role of RIP3 in the necrotic cell death
pathways, and we recently reported that cIAP1/2 depletion by
BV6 treatment facilitates RIP1/3-necrotic complex formation and
cell death[11,12,13,38,45]. Because RIP1 is implicated in many of
the RIP3-dependent necrotic pathways[46], it will be important in
the future to study the role of cIAP1 in the regulation of RIP1-
independent but RIP3-mediated necrosis. A potential model
system for this is the recently reported role of RIP3 during
murine cytomegalovirus infection[47].
Figure 5. Lysine residues K51 and K145 of RIP4 are critical for cIAP1-mediated ubiquitination and NF-kB activation. (A) Flag-tagged
wild type RIP4, K51R, K145R, K158R and K220/221R mutants were ectopically expressed in HEK293T cells together with a NF-kB luciferase reporter.
24h after transfection, lysates were prepared and tested for luciferase activity. Relative luciferase activity is depicted after correction for transfection
efficiency, 6 S.D. (B) Lysates described in (B) were used for western blotting analysis with an anti-Flag antibody in order to detect expression of the
different Flag-tagged RIP4 variants. (C) HEK293T cells were transfected with FLAG-tagged wild-type RIP4, the K51R mutant or with empty vector. The
medium was replaced 8h post-transfection with medium containing, or not, BV6 (1 mM). The RIP4 proteins were immunoprecipitated 18h later in
RIPA buffer using anti-FLAG antibody and ubiquitinated RIP4 proteins were revealed by immunoblotting with anti-FLAG and anti-ubiquitin
antibodies. (D) In vitro ubiquitination assays were performed on in vitro-transcribed and -translated wild-type RIP4, K51R, K145R, K158R and K220/
221R mutants labeled with 35S-methionine. GST or GST-cIAP1 was used as E3 component and UbcH5a as E2 component. The reaction was carried out
in presence of wild-type ubiquitin. RIP4 ubiquitination was revealed by autoradiography.
doi:10.1371/journal.pone.0022356.g005
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RIP4 was initially identified as a PKC-interacting kinase[48,49].
The effect of genetic ablation of RIP4 in the mouse points to a role
in skin development[18], whereas skin-specific transgenic mice
show increased inflammatory responses[19]. Because no receptor
acting upstream of RIP4 has been identified yet, signaling studies
on RIP4 have been limited to overexpression paradigms. When
ectopically expressed, RIP4 leads to the activation of NF-kB and
JNK signaling pathways, which was reported to dependent on its
kinase activity[16,17]. In this study, we found that cIAP1 acts as a
direct E3 ubiquitin ligase for RIP4 and that mutation of lysine
residues K51 and K145 abrogates cIAP1-mediated ubiquitination
of RIP4 and NF-kB activation. We found that both wild-type
RIP4 and the K51R mutant are highly ubiquitinated when
ectopically expressing in HEK293T cells, although with different
ubiquitination patterns (Figure 5C), and that cIAP1/2 depletion
only repressed wild-type RIP4 ubiquitination. These results
indicate that RIP4 is ubiquitinated by several E3 ubiquitin ligases
when ectopically expressed in cells, and that only chains added to
certain Lys residues play a role in NF-kB activation. cIAP1 and
cIAP2 were originally identified as binding partners for the TNF-
associated factors 1 and 2 (TRAF1 and TRAF2)[50], and several
studies have suggested that cIAP1, cIAP2, and TRAF2 function-
ally interact[51,52,53,54,55]. Interestingly, RIP4 binds several
members of the TRAF protein family, and dominant negative
TRAF1, TRAF3 and TRAF6 inhibit RIP4-induced NF-kB
activation[17]. In addition, a link between PKC kinases and
TRAF proteins in IKK complex activation was recently
reported[56]. This observation suggests that all these proteins
might act together to mediate RIP4-dependent IKK complex
activation. However, defects in skin differentiation have not been
reported in cIAP1 or cIAP2-deficient mice, which might be
explained by redundancy between cIAP1/2[57]. Simultaneous
deletion of cIAP1 and cIAP2 in keratinocytes in vivo should provide
insights in their physiological roles in regulating RIP4 function.
Consistent with previous studies, we show that the K51R
mutant, which replaces the essential lysine residue in the conserved
ATP-binding site resulting in loss of RIP4 kinase activity, is
defective for NF-kB activation[16,17]. We found that the K145R
mutation, which also inhibits RIP4 auto-phosphorylation
(Figure 4B–C), similarly inhibited NF-kB activation. Remarkably,
we observed that both mutants are also defective in cIAP1-
mediated ubiquitination, therefore raising the question about the
relative contribution of ubiquitination and RIP4 kinase activity in
the activation of the NF-kB response. We found that depletion of
cIAP1/2 by BV6 treatment greatly repressed RIP4 ubiquitination
and RIP4-mediated NF-kB activation without affecting RIP4
auto-phosphorylation (Figure 4B–5C). Together, these results
suggest that RIP4 auto-phosphorylation might be an early signal
required for cIAP1 to mediate RIP4-dependent NF-kB activation.
In accordance with this view, it is therefore possible that Lys51 and
Lys145 are not acceptor sites for ubiquitination. However, both
residues are conserved between human RIP1-4 proteins, and
Lys140 of RIP1 (homologous to Lys145 of RIP4) has previously
been identified as ubiquitin acceptor site by mass spectrome-
try[58], supporting Lys145 of RIP4 as a potential ubiquitin
acceptor site. Contrary to RIP4, those two residues are most
probably not important for RIP1 and RIP3-mediated NF-kB
activation since this mediatory function was reported to depend on
the ID of RIP1 and on the c-terminal portion of RIP3[23,59]. In
addition, RIP3 K50D mutant (homologous to RIP4 K51R) does
not show defect in NF-kB activation[15]. On the other hand, it
might be interesting in future work to test the effect of mutating
the homologue residues in RIP2 since the KD of RIP2 is essential
for NF-kB activation[22].
In conclusion, this work demonstrates the role of cIAP1/2 as
general regulators of RIP-mediated functions. The fact that cIAP1
conjugates RIP proteins with L48-, Lys63- and linear ubiquitin
chains provides new interpretations of how signaling complexes
might be recruited to the RIPs by ubiquitination. In addition,
those findings suggest new physiological roles for the cIAP1/2 in
RIP3 and RIP4 signaling pathways.
Supporting Information
Figure S1 HEK293T cells were transfected with VSV-
tagged RIP plasmids in the absence or presence of a
Myc-tagged cIAP2 plasmid. cIAP2 was immunoprecipitated
in NP-40 buffer using anti-Myc antibody and coimmunoprecipi-
tated RIPs were revealed by immunoblotting with anti-VSV
antibody. Protein expression in the lysates is shown.
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